These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33051954)

  • 1. Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study.
    Mazloom E; Daneshpazhooh M; Shokouhi Shoormasti R; Balighi K; Mahmoudi H; Moradi Ketisari M; Eslami Faresani V; Ghandi N
    Dermatol Ther; 2020 Nov; 33(6):e14407. PubMed ID: 33051954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
    Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
    J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
    [No Abstract]   [Full Text] [Related]  

  • 3. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris.
    Vinay K; Kanwar AJ; Mittal A; Dogra S; Minz RW; Hashimoto T
    JAMA Dermatol; 2015 Aug; 151(8):878-82. PubMed ID: 25536513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
    Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases.
    Bardazzi F; Loi C; Vara G; Patrizi A; Di Altobrando A
    J Dermatolog Treat; 2022 Feb; 33(1):580-582. PubMed ID: 32068447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rituximab as an adjuvant in the treatment of oral pemphigus vulgaris.
    Fortuna G; Calabria E; Ruoppo E; Adamo D; Aria M; Amato M; Mignogna MD
    J Oral Pathol Med; 2020 Jan; 49(1):91-95. PubMed ID: 31420993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
    Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
    Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant.
    Fortuna G; Calabria E; Aria M; Giudice A; Mignogna MD
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827631
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
    Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
    J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus.
    Shin SH; Kim JY; Kim SC; Kim JH
    J Dermatol; 2024 Aug; 51(8):1104-1107. PubMed ID: 38874429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial.
    Iraji F; Danesh F; Faghihi G; Siadat A; Mokhtari F; Talakoob M; Hafezi H
    Int Immunopharmacol; 2019 Aug; 73():94-97. PubMed ID: 31082727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?
    Balighi K; Hatami P; Sheikh Aboli MJ; Daneshpazhooh M; Ghiasi M; Mahmoudi HR; Aryanian Z
    Dermatol Ther; 2022 Feb; 35(2):e15249. PubMed ID: 34910350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
    El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
    Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
    Róbert L; Kovács A; Sárdy M; Fábián M
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
    Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab.
    Alaeen H; Toosi R; Mahmoudi H; Balighi K; Tavakolpour S; Teimoupour A; Daneshpazhooh M
    Int J Womens Dermatol; 2019 Dec; 5(5):372-377. PubMed ID: 31909160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy for intractable pemphigus: A multicenter, open-label, single-arm, prospective study of 20 Japanese patients.
    Yamagami J; Kurihara Y; Funakoshi T; Saito Y; Tanaka R; Takahashi H; Ujiie H; Iwata H; Hirai Y; Iwatsuki K; Ishii N; Sakurai J; Abe T; Takemura R; Mashino N; Abe M; Amagai M
    J Dermatol; 2023 Feb; 50(2):175-182. PubMed ID: 36196051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
    Keeley JM; Bevans SL; Jaleel T; Sami N
    J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.